Open Demat
    Be a Partner
    Samadhan
    Install App
    Install App

    3351

    524715

    SUNPHARMA

    img img img img
    Compare to down-arrow
    View down-arrow
    Display down-arrow
    Studies down-arrow
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    SUN PHARMACEUTICAL IND L Share Price Today

    SUN PHARMACEUTICAL IND L is currently trading at ₹2014.3, up by ₹24.4 from the previous close. The stock touched an intraday high of ₹2017.30 and a low of ₹1988.00 during the latest trading session. Over the past one year, SUN PHARMACEUTICAL IND L has delivered a return of 16.33%, while the stock has gained 6.13% in the last one month.

    SUN PHARMACEUTICAL IND L performance

    Today’s low Today’s high
    ₹ 1988.00 ₹ 2017.30
    ₹ 2014.70
    52 week low 52 week high
    ₹ 1548.00 ₹ 2016.80
    ₹ 2014.70
    Open Price ₹ 1993.10
    Prev. Close ₹ 1989.90
    Volume (Shares) 1273475.00
    Total traded value ₹ 25656.70
    Upper Circuit ₹ 2188.80
    Lower Circuit ₹ 1791.00
    info

    Investment Returns

    Over 1 Month 6.13% Over 3 Months 11.87% Over 6 Months 25.20% Over 1 Year 16.33%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    SUN PHARMACEUTICAL IND L fundamentals


    • Market cap (Cr) 4,83,082.10
    • P/E Ratio (TTM) 182.04
    • Beta 0.52
    • Book Value / share 93.23
    • Return on equity 12.73%
    • EPS (TTM) 12.27
    • Dividend yield 0.80%
    • Net profit/quarter (Cr) 608.70
    info icon alternate text
    • Market cap (Cr) 4,83,202.10
    • P/E Ratio (TTM) 182.04
    • Beta 0.49
    • Book Value / share 93.23
    • Return on equity 12.73%
    • EPS (TTM) 12.27
    • Dividend yield 0.80%
    • Net profit/quarter (Cr) 608.70
    info icon alternate text

    SUN PHARMACEUTICAL IND L Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 4887.27
    Operating Expense 4137.80
    Net Profit 608.70
    Net Profit Margin (%) 12.45
    Earnings Per Share (EPS) 2.50
    EBITDA 1391.90
    Effective Tax Rate (%) 28.30
    Particulars DEC 2025 (Values in Cr)
    Revenue 5651.21
    Operating Expense 4511.87
    Net Profit 705.44
    Net Profit Margin (%) 12.48
    Earnings Per Share (EPS) 2.90
    EBITDA 1679.80
    Effective Tax Rate (%) 35.69
    Particulars SEP 2025 (Values in Cr)
    Revenue 4511.27
    Operating Expense 3949.15
    Net Profit 564.22
    Net Profit Margin (%) 12.50
    Earnings Per Share (EPS) 2.40
    EBITDA 1256.38
    Effective Tax Rate (%) 16.00
    Particulars JUN 2025 (Values in Cr)
    Revenue 5559.27
    Operating Expense 4234.69
    Net Profit 745.06
    Net Profit Margin (%) 13.40
    Earnings Per Share (EPS) 3.10
    EBITDA 1725.60
    Effective Tax Rate (%) 36.65
    Particulars MAR 2025 (Values in Cr)
    Revenue 7100.65
    Operating Expense 4657.82
    Net Profit 2041.97
    Net Profit Margin (%) 28.75
    Earnings Per Share (EPS) 8.30
    EBITDA 3191.58
    Effective Tax Rate (%) 23.05
    Particulars MAR 2026 (Values in Cr)
    Revenue 20609.02
    Operating Expense 16833.51
    Net Profit 2623.42
    Net Profit Margin (%) 12.72
    Earnings Per Share (EPS) 10.90
    EBITDA 6053.68
    Effective Tax Rate (%) 30.85
    Particulars MAR 2025 (Values in Cr)
    Revenue 22598.40
    Operating Expense 18380.32
    Net Profit 4228.08
    Net Profit Margin (%) 18.70
    Earnings Per Share (EPS) 17.60
    EBITDA 7216.84
    Effective Tax Rate (%) 15.03
    Particulars MAR 2024 (Values in Cr)
    Revenue 19843.53
    Operating Expense 17072.26
    Net Profit 2858.18
    Net Profit Margin (%) 14.40
    Earnings Per Share (EPS) 11.90
    EBITDA 5834.35
    Effective Tax Rate (%) 17.14
    Particulars MAR 2023 (Values in Cr)
    Revenue 20394.63
    Operating Expense 16412.32
    Net Profit 1690.72
    Net Profit Margin (%) 8.29
    Earnings Per Share (EPS) 7.00
    EBITDA 3814.10
    Effective Tax Rate (%) 2.89
    Particulars MAR 2022 (Values in Cr)
    Revenue 15518.50
    Operating Expense 14416.51
    Net Profit -99.99
    Net Profit Margin (%) -0.64
    Earnings Per Share (EPS) -0.40
    EBITDA 2044.91
    Effective Tax Rate (%) 132.58
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 348.31
    ROE % 14.85
    ROCE % 18.72
    Total Debt to Total Equity 0.04
    EBITDA Margin 31.47
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 301.00
    ROE % 16.16
    ROCE % 19.52
    Total Debt to Total Equity 0.04
    EBITDA Margin 31.49
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 265.36
    ROE % 16.13
    ROCE % 17.20
    Total Debt to Total Equity 0.08
    EBITDA Margin 28.63
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 233.38
    ROE % 16.46
    ROCE % 16.79
    Total Debt to Total Equity 0.08
    EBITDA Margin 27.59
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 200.11
    ROE % 14.50
    ROCE % 17.97
    Total Debt to Total Equity 0.05
    EBITDA Margin 29.19
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 93.24
    ROE % 12.73
    ROCE % 14.47
    Total Debt to Total Equity 0.55
    EBITDA Margin 31.85
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 99.61
    ROE % 17.77
    ROCE % 16.18
    Total Debt to Total Equity 0.49
    EBITDA Margin 31.41
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 98.76
    ROE % 12.05
    ROCE % 12.22
    Total Debt to Total Equity 0.40
    EBITDA Margin 28.78
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 98.98
    ROE % 13.89
    ROCE % 16.26
    Total Debt to Total Equity 0.27
    EBITDA Margin 32.43
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 102.48
    ROE % -5.19
    ROCE % 7.47
    Total Debt to Total Equity 0.24
    EBITDA Margin 24.56
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 11603.08
    Total Assets 108785.22
    Total Liabilities 108785.22
    Total Equity 83879.74
    Share Outstanding 239
    Price to Book Ratio 18.85
    Return on Assets (%) 10.55
    Return on Capital (%) 13.05
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 11331.62
    Total Assets 92100.58
    Total Liabilities 92100.58
    Total Equity 72485.95
    Share Outstanding 239
    Price to Book Ratio 17.42
    Return on Assets (%) 11.86
    Return on Capital (%) 14.7
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 10520.68
    Total Assets 85499.65
    Total Liabilities 85499.65
    Total Equity 67125.94
    Share Outstanding 239
    Price to Book Ratio 16.41
    Return on Assets (%) 11.20
    Return on Capital (%) 13.69
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 5770.29
    Total Assets 80743.59
    Total Liabilities 80743.59
    Total Equity 59315.47
    Share Outstanding 239
    Price to Book Ratio 9.93
    Return on Assets (%) 10.49
    Return on Capital (%) 12.93
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 5033.35
    Total Assets 69807.77
    Total Liabilities 69807.77
    Total Equity 51066.11
    Share Outstanding 239
    Price to Book Ratio 8.93
    Return on Assets (%) 4.68
    Return on Capital (%) 6.29
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 436.97
    Total Assets 43059.54
    Total Liabilities 43059.54
    Total Equity 22370.76
    Share Outstanding 239
    Price to Book Ratio 18.85
    Return on Assets (%) 6.09
    Return on Capital (%) 7.33
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 911.05
    Total Assets 43878.47
    Total Liabilities 43878.47
    Total Equity 23900.29
    Share Outstanding 239
    Price to Book Ratio 17.42
    Return on Assets (%) 9.63
    Return on Capital (%) 11.86
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 338.39
    Total Assets 41064.79
    Total Liabilities 41064.79
    Total Equity 23694.40
    Share Outstanding 239
    Price to Book Ratio 16.41
    Return on Assets (%) 6.96
    Return on Capital (%) 8.23
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 421.28
    Total Assets 40987.49
    Total Liabilities 40987.49
    Total Equity 23748.36
    Share Outstanding 239
    Price to Book Ratio 9.93
    Return on Assets (%) 4.12
    Return on Capital (%) 5.39
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 534.96
    Total Assets 40765.48
    Total Liabilities 40765.48
    Total Equity 24587.95
    Share Outstanding 239
    Price to Book Ratio 8.93
    Return on Assets (%) -0.24
    Return on Capital (%) -0.34
    Particulars MAR 2026 (Values in Cr)
    Net Income 15118.88
    Cash from Operations 14733.12
    Cash from Investing -11344.05
    Cash from Financing -2512.55
    Net change in Cash -1437.42
    Free Cash Flow 18342.49
    Particulars MAR 2025 (Values in Cr)
    Net Income 13752.13
    Cash from Operations 14548.93
    Cash from Investing -5306.16
    Cash from Financing -7905.82
    Net change in Cash 860.11
    Free Cash Flow 16677.51
    Particulars MAR 2024 (Values in Cr)
    Net Income 11087.89
    Cash from Operations 13704.42
    Cash from Investing -690.20
    Cash from Financing -6710.16
    Net change in Cash 4734.62
    Free Cash Flow 15906.23
    Particulars MAR 2023 (Values in Cr)
    Net Income 9408.43
    Cash from Operations 6469.17
    Cash from Investing -7943.68
    Cash from Financing 2376.07
    Net change in Cash -608.28
    Free Cash Flow 8554.75
    Particulars MAR 2022 (Values in Cr)
    Net Income 4481.32
    Cash from Operations 8015.32
    Cash from Investing -5724.74
    Cash from Financing -5193.46
    Net change in Cash -1933.66
    Free Cash Flow 9510.36
    Particulars MAR 2026 (Values in Cr)
    Net Income 3794.12
    Cash from Operations 6901.54
    Cash from Investing -1380.95
    Cash from Financing -5230.18
    Net change in Cash -110.26
    Free Cash Flow 8444.32
    Particulars MAR 2025 (Values in Cr)
    Net Income 4976.21
    Cash from Operations 4385.70
    Cash from Investing -258.17
    Cash from Financing -3836.13
    Net change in Cash 157.67
    Free Cash Flow 5154.73
    Particulars MAR 2024 (Values in Cr)
    Net Income 3449.65
    Cash from Operations 49.45
    Cash from Investing -262.91
    Cash from Financing 473.95
    Net change in Cash -81.38
    Free Cash Flow 798.69
    Particulars MAR 2023 (Values in Cr)
    Net Income 1741.05
    Cash from Operations 939.07
    Cash from Investing -705.17
    Cash from Financing 169.31
    Net change in Cash -28.78
    Free Cash Flow 1901.50
    Particulars MAR 2022 (Values in Cr)
    Net Income 306.86
    Cash from Operations 5476.82
    Cash from Investing -2702.10
    Cash from Financing -4870.85
    Net change in Cash 63.41
    Free Cash Flow 6326.71
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.89 12.82 1.49 236.72 23.12 38.85
    BLISS GVS PHARMA LTD. 458.05 36.82 4.07 4857.91 118.35 552.90
    CIPLA LTD 1473.45 33.26 3.45 119031.97 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 451.45 21.12 3.26 1328.66 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.89 21.60 3.97 236.72 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 516.80 23.16 4.03 1494.10 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8179.35 106.89 23.42 20448.38 7630.00 9850.00
    BLISS GVS PHARMA LTD. 458.05 49.52 4.20 4857.91 118.35 552.90

    SUN PHARMACEUTICAL IND L shareholding pattern

    Holding
    8.81%
    54.47%
    14.53%
    22.17%
    1.65%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    SUN PHARMACEUTICAL IND L Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    2013.40 1.18 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 1971.60
    • 26 Days 1923.70
    • 10 Days 1959.10
    • 50 Days 1885.10
    • 12 Days 1954.40
    • 100 Days 1836.30
    • 20 Days 1936.00
    • 200 Days 1790.80
    1981.00 PIVOT
    First Support 1969.30 First Resistance 2001.60 Second Support 1948.70 Second Resistance 2013.30 Third Support 1937.00 Third Resistance 2033.90
    RSI 68.43 ADX 46.84 MACD 30.63 Williams % R -3.73 Commodity Channel Index (CCI) 143.84
    Date 2026-07-29 Week 2191144.00 Same Day 1696689.00 Month 1444566.00
    1 Year 0.53 3 Year 0.52
    Over 1 Month
    6.13% down
    Over 1 Year
    16.33% down
    Over 3 Months
    11.87% down
    Over 3 Years
    20.28% down
    Over 6 Months
    25.20% down
    Over 5 Years
    23.13% down

    SUN PHARMACEUTICAL IND L Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    07 Jul 2026 5.0 Final 07 Jul 2026 Equity shares
    05 Feb 2026 11.0 Interim 05 Feb 2026 Equity shares
    07 Jul 2025 5.5 Final 07 Jul 2025 Equity shares
    06 Feb 2025 10.5 Interim 06 Feb 2025 Equity shares
    12 Jul 2024 5.0 Final 12 Jul 2024 Equity shares
    09 Feb 2024 8.5 Interim 09 Feb 2024 Equity shares
    28 Jul 2023 4.0 Final 28 Jul 2023 Equity shares
    08 Feb 2023 7.5 Interim 08 Feb 2023 Equity shares
    19 Aug 2022 3.0 Final 22 Aug 2022 Equity shares
    09 Feb 2022 7.0 Interim 10 Feb 2022 Equity shares
    23 Aug 2021 2.0 Final 25 Aug 2021 Equity shares
    09 Feb 2021 5.5 Interim 10 Feb 2021 Equity shares
    19 Aug 2020 1.0 Final 21 Aug 2020 Equity shares
    17 Feb 2020 3.0 Interim 18 Feb 2020 Equity shares
    20 Aug 2019 2.75 Final 22 Aug 2019 Equity shares
    17 Sep 2018 2.0 Final 19 Sep 2018 Equity shares
    18 Sep 2017 3.5 Final 20 Sep 2017 Equity shares
    08 Sep 2016 1.0 Final 10 Sep 2016 Equity shares
    21 Oct 2015 3.0 Final 24 Oct 2015 Equity shares
    11 Sep 2014 1.5 Final 13 Sep 2014 Equity shares
    19 Sep 2013 2.5 Final 23 Sep 2013 Equity shares
    14 Aug 2012 4.25 Interim 16 Aug 2012 Equity shares
    02 Sep 2011 3.5 Final 06 Sep 2011 Equity shares
    09 Sep 2010 13.75 Final 14 Sep 2010 Equity shares
    21 Aug 2009 13.75 Final 25 Aug 2009 Equity shares
    25 Aug 2008 10.5 Final 27 Aug 2008 Equity shares
    15 Mar 2007 6.75 Final 16 Mar 2007 Equity shares
    19 Sep 2005 0.0 Final 21 Sep 2005 Equity shares
    Ex-Date Ex-Bonus Ratio
    30 Jul 2013 29 Jul 2013 1:1
    29 May 2004 27 May 2004 1:1
    23 Mar 2000 06 Mar 2000 2:1
    Ex-Date Old FV NEW FV Record Date
    25 Nov 2010 5.0 1.0 26 Nov 2010
    13 Jan 2003 10.0 5.0 21 Jan 2003
    Dividend date Dividend amount Dividend type Record date Instrument type
    07 Jul 2026 5.0 Final 07 Jul 2026 Equity shares
    05 Feb 2026 11.0 Interim 05 Feb 2026 Equity shares
    07 Jul 2025 5.5 Final 07 Jul 2025 Equity shares
    06 Feb 2025 10.5 Interim 06 Feb 2025 Equity shares
    12 Jul 2024 5.0 Final 12 Jul 2024 Equity shares
    09 Feb 2024 8.5 Interim 09 Feb 2024 Equity shares
    28 Jul 2023 4.0 Final 28 Jul 2023 Equity shares
    08 Feb 2023 7.5 Interim 08 Feb 2023 Equity shares
    19 Aug 2022 3.0 Final 22 Aug 2022 Equity shares
    09 Feb 2022 7.0 Interim 10 Feb 2022 Equity shares
    23 Aug 2021 2.0 Final 25 Aug 2021 Equity shares
    09 Feb 2021 5.5 Interim 10 Feb 2021 Equity shares
    19 Aug 2020 1.0 Final 21 Aug 2020 Equity shares
    17 Feb 2020 3.0 Interim 18 Feb 2020 Equity shares
    20 Aug 2019 2.75 Final 22 Aug 2019 Equity shares
    17 Sep 2018 2.0 Final 19 Sep 2018 Equity shares
    18 Sep 2017 3.5 Final 20 Sep 2017 Equity shares
    08 Sep 2016 1.0 Final 10 Sep 2016 Equity shares
    21 Oct 2015 3.0 Final 24 Oct 2015 Equity shares
    11 Sep 2014 1.5 Final 13 Sep 2014 Equity shares
    19 Sep 2013 2.5 Final 23 Sep 2013 Equity shares
    14 Aug 2012 4.25 Interim 16 Aug 2012 Equity shares
    02 Sep 2011 3.5 Final 06 Sep 2011 Equity shares
    09 Sep 2010 13.75 Final 14 Sep 2010 Equity shares
    21 Aug 2009 13.75 Final 25 Aug 2009 Equity shares
    25 Aug 2008 10.5 Final 27 Aug 2008 Equity shares
    15 Mar 2007 6.75 Final 16 Mar 2007 Equity shares
    19 Sep 2005 0.0 Final 21 Sep 2005 Equity shares
    Ex-Date Ex-Bonus Ratio
    30 Jul 2013 29 Jul 2013 1:1
    29 May 2004 27 May 2004 1:1
    23 Mar 2000 06 Mar 2000 2:1
    Ex-Date Old FV NEW FV Record Date
    25 Nov 2010 5.0 1.0 26 Nov 2010
    13 Jan 2003 10.0 5.0 21 Jan 2003

    Top Gainers

    up-arrow (%)

    Top Losers

    up-arrow (%)

    Sun Pharmaceutical Industries Ltd Overview

    Sun Pharmaceutical Industries Ltd, headquartered in India, is a global frontrunner in the pharmaceutical sector, holding the title of the largest pharmaceutical company in India. Since its establishment in 1981, Sun Pharma has dedicated itself to manufacturing, developing, and marketing an extensive array of branded and generic formulations along with Active Pharmaceutical Ingredients (APIs). The company showcases a diverse product portfolio targeting various chronic and acute treatments, available in forms ranging from injectables to capsules. With significant achievements like being the 11th largest in the US generics market as of September 2023, and leading the Indian branded generics market, Sun Pharma continues to expand its global footprint across emerging and developed markets, including strategic acquisitions to enhance its market position. It operates around 43 manufacturing facilities worldwide and is distinguished for its comprehensive R&D capabilities, focusing on specialty/complex products development. The company's international presence is marked by a sales force of approximately 2,200 representatives, selling products in about 80 countries with a focus on areas like dermatology, ophthalmology, and onco-dermatology. Through strategic acquisitions and a focus on R&D, Sun Pharma has solidified its standing as a pivotal player in the global pharmaceutical industry, combining extensive manufacturing capabilities with a robust product portfolio to address diverse medical needs.

    Sun Pharma share result highlights

    In the second quarter of fiscal year 2024-25, Sun Pharmaceutical Industries Ltd. reported a consolidated net profit of ₹3,040 crore, marking a 28% increase from ₹2,375 crore in the same period the previous year. Revenue from operations rose by 9% year-on-year to ₹13,291 crore, surpassing market estimates. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 24% year-on-year to ₹3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% year-on-year to ₹4,265 crore, representing 32% of total sales. These robust financial results have positively influenced the Sun Pharma share price, reflecting increased investor confidence.

    Sun Pharma share annual reports

    The 2023-24 annual report of Sun Pharmaceutical Industries Ltd. provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹45,000 crore, registering a growth of 5% from the previous year. The report highlights Sun Pharma's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Sun Pharma share price by showcasing the company's commitment to growth and profitability.

    Sun Pharma share dividend

    For the fiscal year 2023-24, Sun Pharmaceutical Industries Ltd. declared a total dividend of ₹12 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Sun Pharma share price by enhancing investor confidence.

    Popular FAQs

    1. Who is the CEO of Sun Pharma Ltd?

    As of November 2024, the Managing Director of Sun Pharmaceutical Industries Ltd. is Mr. Dilip Shanghvi. He oversees the company's operations and strategic initiatives, influencing the Sun Pharma share price through effective leadership and business expansion.

     

    2. When was Sun Pharma Ltd established?

    Sun Pharmaceutical Industries Ltd. was established in 1983. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Sun Pharma share price through its extensive operations and market presence.

     

    3. What factors influence Sun Pharma Ltd share price fluctuations?

    The Sun Pharma share price is influenced by various factors, including the company's financial performance, expansion of product portfolios, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

     

    4. Is Sun Pharma debt free?

    No, Sun Pharmaceutical Industries Ltd. is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Sun Pharma share price.

     

    5. What is the CAGR of Sun Pharma share?

    Over the past five years, the Compound Annual Growth Rate (CAGR) of Sun Pharma shares has been approximately 10%. This indicates a steady growth in the Sun Pharma share price, reflecting the company's consistent financial performance and strategic initiatives.

     

    6. How has the Sun Pharma share price performed over the past year?

    Over the past year, the Sun Pharma share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Dilip S Shanghvi Chairman / Executive Director / M D / Promoter
    Kirti Wardhaman Ganorkar Executive Director & MD
    Pawan Goenka Lead Independent Non Executive Director
    Gautam Doshi Independent Non Exe. Director
    Rolf Hoffmann Independent Non Exe. Director
    Aalok Dilip Shanghvi ED / WTD / CFO / Promoter
    Vidhi Shanghvi E D & Wholetime Director
    Satyavati Berera Independent Non Exe. Director
    Andreas Busch Independent Non Exe. Director
    Anoop Anjanikumar Deshpande Company Sec. & Compli. Officer

    Similar stocks

    similar-logo DIVISLAB
    1.70%
    7917 132.50
    down-arrow
    similar-logo TORNTPHARM
    0.05%
    4881.1 2.60
    down-arrow
    similar-logo CIPLA
    -0.21%
    1471.2 -3.10
    down-arrow
    similar-logo ZYDUSLIFE
    -0.17%
    1120.7 -2.00
    down-arrow
    similar-logo LUPIN
    -0.73%
    2429.1 -17.89
    down-arrow
    similar-logo MANKIND
    -0.78%
    2572.4 -20.30
    down-arrow
    similar-logo LAURUSLABS
    0.13%
    1783.7 2.39
    down-arrow
    similar-logo DRREDDY
    0.06%
    1143.1 0.79
    down-arrow
    similar-logo AUROPHARMA
    -0.59%
    1581.3 -9.39
    down-arrow
    similar-logo ALKEM
    2.64%
    5822.5 150.00
    down-arrow

    Frequently Asked Questions

    What is the Current Share Price of Sun Pharmaceutical Industries Ltd?

    Answer Field

    Sun Pharmaceutical Industries Ltd share price is for NSE ₹ 2,014.30 & for BSE ₹ 2,014.45 as on Jul 30 2026 02:06 PM.

    What is the Market Cap of Sun Pharmaceutical Industries Ltd Share?

    Answer Field

    The market cap of Sun Pharmaceutical Industries Ltd for NSE ₹ 0.04 & for BSE ₹ 0.04 as on Jul 30 2026 02:06 PM.

    What is the 52 Week High and Low of Sun Pharmaceutical Industries Ltd?

    Answer Field

    The 52 Week High and Low of Sun Pharmaceutical Industries Ltd for NSE is ₹ 2,016.80 and ₹ 1,548.00 and for BSE is ₹ 2,017.00 and ₹ 1,547.25.

    What is 1 year return for Sun Pharmaceutical Industries Ltd?

    Answer Field

    The 1 year returns on the stock has been 16.33%.

    What is the P/E Ratio of Sun Pharmaceutical Industries Ltd Share?

    Answer Field

    As on Jul 30 2026 02:06 PM the price-to-earnings (PE) ratio for Sun Pharmaceutical Industries Ltd share is 182.04.

    What is the PB ratio of Sun Pharmaceutical Industries Ltd Share?

    Answer Field

    As on Jul 30 2026 02:06 PM, the price-to-book (PB) ratio for Sun Pharmaceutical Industries Ltd share is 93.23.

    How to Buy Sun Pharmaceutical Industries Ltd Share?

    Answer Field

    You can trade in Sun Pharmaceutical Industries Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Sun Pharmaceutical Industries Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Sun Pharmaceutical Industries Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Sun Pharmaceutical Industries Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    Who is the CEO of Sun Pharma Ltd?

    Answer Field

    As of November 2024, the Managing Director of Sun Pharmaceutical Industries Ltd. is Mr. Dilip Shanghvi. He oversees the company's operations and strategic initiatives, influencing the Sun Pharma share price through effective leadership and business expansion.

    When was Sun Pharma Ltd established?

    Answer Field

    Sun Pharmaceutical Industries Ltd. was established in 1983. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Sun Pharma share price through its extensive operations and market presence.

    What factors influence Sun Pharma Ltd share price fluctuations?

    Answer Field

    The Sun Pharma share price is influenced by various factors, including the company's financial performance, expansion of product portfolios, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

    Is Sun Pharma debt free?

    Answer Field

    No, Sun Pharmaceutical Industries Ltd. is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Sun Pharma share price.

    What is the CAGR of Sun Pharma share?

    Answer Field

    Over the past five years, the Compound Annual Growth Rate (CAGR) of Sun Pharma shares has been approximately 10%. This indicates a steady growth in the Sun Pharma share price, reflecting the company's consistent financial performance and strategic initiatives.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Products

    arrow

    Calculators

    arrow

    Mutual Funds & SIP

    arrow

    Important Links

    arrow

    Explore

    arrow

    Corporate

    arrow

    Discover

    arrow

    Popular Stocks

    arrow

    Indian Indices

    arrow

    Global Indices

    arrow

    Sector Wise Stocks

    arrow

    IPO

    arrow

    ATTENTION INVESTORS:

    “Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

    "Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

    " We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

    "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

    "We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

    Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

    Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

    BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

    BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

    Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

    Please Note:

    1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

    2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

    3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

    4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

    5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

    Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

    If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email us or call on the toll free number.

    Advisory for Investors : NSE | BSE

    We also do pro-account trading in Equity & Derivatives Segment.

    Filling complaints on SCORES/SMARTODR Portal - Easy & Quick

    A.  Register on SCORES/SMARTODR portal B. Mandatory details for filling complaints on SCORES/SMARTODR:(Name, PAN, Address, Mobile Number, Email ID) C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances / Dispute.

    SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

    Compliance officer:

    Mr. Harinatha Reddy Muthumula
    TEL: 020-48574486
    Email for any investor grievances or write to us for DP related matters.

    DISCLAIMER

    STANDARD DISCLAIMER

    Investments in the securities market are subject to market risk, read all related documents carefully before investing.

    Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

    Website: Bajaj Broking

    RESEARCH DISCLAIMER

    Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

    Details of Compliance Officer: 

    Mr. Harinatha Reddy Muthumula  (For Broking/DP/Research)
    Email | Contact No.: 020-4857 4486 

    Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

    DISCLOSURES

    Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

    Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

    DISCLAIMER

    This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

    This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

    The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

    ADDITIONAL DISCLAIMER FOR U.S. PERSONS

    Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

    ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

    Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

    This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

    DISCLAIMER FOR REPORT

    DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

    Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

    This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

    This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

    We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

    Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

    Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

    Research analyst has served as an officer, director or employee of subject Company: No  

    Bajaj Financial Securities Limited has financial interest in the subject companies: No  

    Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

    Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

    Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

    Subject company may have been client during twelve months preceding the date of distribution of the research report.  

    There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

    ANALYST CERTIFICATION

    The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

    RISK DISCLOSURE ON DERIVATIVES

    • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
    • On an average, loss makers registered net trading loss close to ₹ 50,000.
    • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
    • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

    SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

    BROKERAGE DISCLAIMER

    All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

    MTF 

    As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

    US INVESTING

    International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

    IPO 

    This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

    SCREENERS 

    Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

    SECURITIES 

    Securities quoted are exemplary and not recommendatory. 

    IPV 

    Account would be open after all procedure relating to IPV and client due diligence is completed. 

    IMAGES 

    The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

    THIRD PARTY PRODUCT DISCLAIMER

    Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

    DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

    As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.